| Market Cap | 184.84M | P/E | - | EPS this Y | 86.20% | Ern Qtrly Grth | - |
| Income | -48.13M | Forward P/E | -3.21 | EPS next Y | 109.10% | 50D Avg Chg | 19.00% |
| Sales | 136.36M | PEG | -0.39 | EPS past 5Y | -43.36% | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 47.50% | 52W High Chg | -73.00% |
| Recommedations | 1.70 | Quick Ratio | 1.76 | Shares Outstanding | 151.67M | 52W Low Chg | 44.00% |
| Insider Own | 0.69% | ROA | -8.58% | Shares Float | 115.73M | Beta | 1.80 |
| Inst Own | 86.91% | ROE | - | Shares Shorted/Prior | 35.44M/35.96M | Price | 1.54 |
| Gross Margin | 29.76% | Profit Margin | -35.29% | Avg. Volume | 2,296,511 | Target Price | 6.75 |
| Oper. Margin | -17.89% | Earnings Date | Nov 12 | Volume | 1,380,581 | Change | -4.35% |
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Needham | Buy | Sep 25, 24 |
| Needham | Buy | Aug 7, 24 |
| Rodman & Renshaw | Buy | Jun 13, 24 |
| Needham | Buy | May 16, 24 |
| Needham | Buy | May 8, 24 |
| Capital One | Overweight | Apr 23, 24 |
| Needham | Buy | Apr 11, 24 |
| Needham | Buy | Mar 13, 24 |
| Needham | Buy | Nov 15, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Forbes William P | EVP, Chief Developme.. EVP, Chief Development Officer | Nov 17 | Buy | 1.09 | 25,000 | 27,250 | 79,000 | 11/21/23 |
| Forbes William P | EVP, Chief Developme.. EVP, Chief Development Officer | Nov 16 | Buy | 0.9399 | 50,000 | 46,995 | 54,000 | 11/20/23 |
| MANHARD KIMBERLY | EVP, Drug Developmen.. EVP, Drug Development | May 03 | Sell | 4.76 | 1,504 | 7,159 | 10,872 | 05/04/22 |
| Christian Waage | Director Director | Dec 21 | Sell | 9.73 | 300 | 2,919 | 3,200 | 12/23/21 |
| Johnson Craig A | Director Director | Dec 21 | Sell | 9.73 | 250 | 2,432 | 2,840 | 12/23/21 |
| MANHARD KIMBERLY | EVP, Drug Developmen.. EVP, Drug Development | Dec 23 | Option | 13 | 10,000 | 130,000 | 10,000 | 12/23/20 |
| MANHARD KIMBERLY | EVP, Drug Developmen.. EVP, Drug Development | Dec 23 | Sell | 20 | 10,000 | 200,000 | 12/23/20 |